Robert Cyran, U.S. tech columnist, joined Breakingviews in London in 2003 and moved four years later to New York, where he continues to cover global technology, pharmaceuticals and special situations. Robert began his career at Forbes magazine, where he assisted in the startup of the international version of the magazine. Before working at Breakingviews he worked as a market researcher and reporter covering the pharmaceutical industry. Robert has a Masters degree in economics from Birmingham University and an undergraduate degree from George Washington University. Follow Rob on Twitter @rob_cyran
- Tel: +1 646 223 6083
- E-mail: email@example.com
Facebook, Apple, Amazon and Microsoft lost nearly $200 bln of value in a week. China’s woes sparked the rout, but the problem was investors’ giddy faith in growth. Public tech stocks may recover. Fantasy valuations of private firms like Uber, though, will take the bigger hit.
Fracker Pioneer National is about to start using treated sewage in its wells. United Airlines may use animal waste as fuel. Recycling feces is now efficient enough to produce both energy and drinking water. This new spin on natural gas offers benefits for the land and air, too.
The acquisitive drug firm is buying Sprout, the maker of just-approved “female Viagra.” Valeant will have gotten a bargain if it can crank out billions in annual sales. Snag is, the drug isn’t very effective, it has bad side effects, and regulatory restrictions may crimp sales.
- "Female Viagra"-maker slips the FDA a roofie
- Wal-Mart's "investment" in wages may pay off
- John Malone takes home shopping over the top
- Twitter's mealy-mouthed strategy is hard to follow
- Billionaire's biotech IPO rides high on hope
- Allergan turns itself into M&A lab experiment
- Breakdown: Watchdogs chew on health insurer deals